See today's BioWorld Science
To read the full story, subscribe or sign in.
Obstetrics

Comanche’s siRNA therapy CBP-4888 cleared by FDA to enter clinic for pre-eclampsia

March 31, 2023
Comanche Biopharma Corp. has received IND clearance from the FDA to conduct a first-in-human study of CBP-4888, its novel, small interfering ribonucleic acid (siRNA) therapy to treat pre-eclampsia.
BioWorld Science Gynecology/obstetrics FDA IND